Skip to main content
Top
Published in: Diabetologia 12/2010

01-12-2010 | Article

Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study

Authors: H. C. Gerstein, S. Islam, S. Anand, W. Almahmeed, A. Damasceno, A. Dans, C. C. Lang, M. A. Luna, M. McQueen, S. Rangarajan, A. Rosengren, X. Wang, S. Yusuf

Published in: Diabetologia | Issue 12/2010

Login to get access

Abstract

Aims/hypothesis

Although diabetes is an established risk factor for myocardial infarction (MI), disease control may vary. HbA1c is a reliable index of ambient glucose levels and may provide more information on MI risk than diabetes status.

Methods

The relationship between HbA1c levels in MI patients and controls who participated in the 52 country INTERHEART study was analysed.

Results

In 15,780 participants with a HbA1c value (1,993 of whom had diabetes), the mean (SD) levels for HbA1c were 6.15% (1.10) in the 6,761 MI patients and 5.85% (0.80) in the control participants. After adjustment for age, sex and nine major MI risk factors (including diabetes), higher HbA1c fifths above the lowest fifth (HbA1c <5.4%) were associated with progressively higher OR of MI, with OR for the highest HbA1c fifth (≥6.12%) being 1.55 (95% CI 1.37–1.75). When analysed as a continuous variable after adjustment for the same factors, every 1% higher HbA1c value was associated with 19% (95% CI 14–23) higher odds of MI, while every 0.5% higher HbA1c was associated with 9% higher odds of MI (95% CI 7–11). Concordant relationships were noted across subgroups, with a higher OR noted in younger people, patients without diabetes or hypertension, and those from some regions and ethnicities.

Conclusions/interpretation

The HbA1c value provides more information on MI odds than self-reported diabetes status or many other established risk factors. Every 1% increment independently predicts a 19% higher odds of MI after accounting for other MI risk factors including diabetes.
Literature
1.
go back to reference International Diabetes Federation (2008) Prevalence Estimates of Diabetes 2007. Diabetes Atlas, 3rd edn. IDF, Brussels International Diabetes Federation (2008) Prevalence Estimates of Diabetes 2007. Diabetes Atlas, 3rd edn. IDF, Brussels
2.
go back to reference Lipscombe LL, Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369:750–756CrossRefPubMed Lipscombe LL, Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369:750–756CrossRefPubMed
4.
go back to reference Lawes CM, Parag V, Bennett DA et al (2004) Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diab Care 27:2836–2842CrossRef Lawes CM, Parag V, Bennett DA et al (2004) Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diab Care 27:2836–2842CrossRef
5.
go back to reference Held C, Gerstein HC, Yusuf S et al (2007) Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115:1371–1375CrossRefPubMed Held C, Gerstein HC, Yusuf S et al (2007) Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115:1371–1375CrossRefPubMed
6.
go back to reference Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG (2006) Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diab Care 29:26–31CrossRef Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG (2006) Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diab Care 29:26–31CrossRef
7.
go back to reference DECODE Study Group EDEG (2003) Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diab Care 26:688–696CrossRef DECODE Study Group EDEG (2003) Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diab Care 26:688–696CrossRef
8.
go back to reference Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413–420PubMed Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413–420PubMed
9.
go back to reference Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916CrossRefPubMed Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916CrossRefPubMed
10.
go back to reference Gerstein HC, Swedberg K, Carlsson J et al (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 168:1699–1704CrossRefPubMed Gerstein HC, Swedberg K, Carlsson J et al (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 168:1699–1704CrossRefPubMed
11.
go back to reference Bartnik M, Ryden L, Ferrari R et al (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880–1890CrossRefPubMed Bartnik M, Ryden L, Ferrari R et al (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880–1890CrossRefPubMed
12.
go back to reference Hu DY, Pan CY, Yu JM (2006) The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 27:2573–2579CrossRefPubMed Hu DY, Pan CY, Yu JM (2006) The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 27:2573–2579CrossRefPubMed
13.
go back to reference Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952CrossRefPubMed Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952CrossRefPubMed
14.
go back to reference Stevenson T (1999) Glycosal: the first rapid, point-of-care test for the determination of hemoglobin A1c in patients with diabetes. Diabetes Technol Ther 1:425–431CrossRefPubMed Stevenson T (1999) Glycosal: the first rapid, point-of-care test for the determination of hemoglobin A1c in patients with diabetes. Diabetes Technol Ther 1:425–431CrossRefPubMed
15.
go back to reference McQueen MJ, Hawken S, Wang X et al (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372:224–233CrossRefPubMed McQueen MJ, Hawken S, Wang X et al (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372:224–233CrossRefPubMed
16.
go back to reference Rosengren A, Hawken S, Ounpuu S et al (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 364:953–962CrossRefPubMed Rosengren A, Hawken S, Ounpuu S et al (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 364:953–962CrossRefPubMed
17.
go back to reference Norhammar A, Tenerz A, Nilsson G et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144CrossRefPubMed Norhammar A, Tenerz A, Nilsson G et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144CrossRefPubMed
18.
go back to reference Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811CrossRefPubMed Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811CrossRefPubMed
19.
go back to reference Origin Trial Investigators (2008) Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155:26–32 Origin Trial Investigators (2008) Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155:26–32
20.
go back to reference Califf RM, Boolell M, Haffner SM et al (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 156:623–632CrossRefPubMed Califf RM, Boolell M, Haffner SM et al (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 156:623–632CrossRefPubMed
22.
go back to reference Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772CrossRefPubMed Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772CrossRefPubMed
23.
go back to reference Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19:604–612 Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19:604–612
24.
go back to reference Gerstein HC (2009) Is it possible to reduce cardiovascular risk with glucose-lowering approaches? Nat Rev Endocrinol 5:270–275CrossRefPubMed Gerstein HC (2009) Is it possible to reduce cardiovascular risk with glucose-lowering approaches? Nat Rev Endocrinol 5:270–275CrossRefPubMed
Metadata
Title
Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study
Authors
H. C. Gerstein
S. Islam
S. Anand
W. Almahmeed
A. Damasceno
A. Dans
C. C. Lang
M. A. Luna
M. McQueen
S. Rangarajan
A. Rosengren
X. Wang
S. Yusuf
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1871-0

Other articles of this Issue 12/2010

Diabetologia 12/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.